Home » Non-Hodgkin’s Lymphoma Pipeline Experiences Momentum:


Los Angeles, USA, Aug. 26, 2021 (GLOBE NEWSWIRE) — Non-Hodgkin’s Lymphoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline 

Increasing awareness about the condition, improved diagnostic techniques and a robust drug pipeline promises a better future Non-Hodgkin’s Lymphoma Space Outlook.

DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) Pipeline Insights report lays down a holistic coverage of the available therapies, Non-Hodgkin’s Lymphoma pipeline therapies in different phases of clinical development, key companies active in the NHL pipeline domain, drivers and barriers in the successful launch of the therapies and future trends. 

Some of the notable pointers extracted from the Non-Hodgkin’s Lymphoma Pipeline report:

  • DelveInsight’s analysis depicts a robust Non-Hodgkin’s Lymphoma Pipeline with 150+ active players in the domain working on 150+ pipeline therapies
  • Key Non-Hodgkin’s Lymphoma pipeline therapies such as Obinutuzumab, Abemaciclib, Ibrutinib, CPI 818, Devimistat, Venetoclax, Loncastuximab tesirine, LAM-002, HMPL-523, Venetoclax, Ibrutinib, Naratuximab emtansine, NKTR-255, LOXO-305, LAM–002, CNCT19, GB226, BI-1206, CAR-CD19 T Cells, AUTO4, TT11, CC-99282, AB-205  and others are under investigation in different phases of clinical trials for the treatment of Non-Hodgkin’s Lymphoma. 
  • Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics among several others are some of the prominent pharma companies working in the space. 
  • In August 2021, HUTCHMED Limited and Epizyme, Inc. announced a collaboration to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
  • Naratuximab emtansine (Debio 1562), an antibody-drug conjugate (ADC) targeting CD37, is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin’s lymphomas (NHL). 
  • The development and planned commercialization of zandelisib are being conducted in partnership with Kyowa Kirin Co., Ltd. Zandelisib is being evaluated in multiple clinical studies by MEI Pharma, including COASTAL, a Phase III study, and TIDAL, a Phase II study, both of which are evaluating zandelisib in patients with relapsed and refractory follicular and marginal zone lymphomas.
  • Polatuzumab vedotin (Anti-CD79b, DCDS4501A, RG7596), an antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against CD79b, link to the small molecule, cytotoxic, microtubule-disrupting agent, monomethyl auristatin E (MMAE) is being developed by Genentech.
  • 3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin late-stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment.
  • Bristol-Myers Squibb, Pharmacyclics and Janssen Research & Development have entered into a collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Non-Hodgkin’s Lymphoma Emerging Therapies and Forecast 

The Non-Hodgkin’s Lymphoma Pipeline report offers insights into ongoing clinical trials, deals, mergers & acquisitions taking place in the Non-Hodgkin’s Lymphoma domain, recent approvals and failures in space, and growth prospects across the Non-Hodgkin’s Lymphoma domain.

Non-Hodgkin’s Lymphoma Overview

Non-Hodgkin’s Lymphoma (NHL) is a cancer of the lymphatic system that develops from lymphocytes. Non-Hodgkin lymphoma can be further subdivided into more than 30 types depending on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). They can be further labeled as either aggressive (fast-growing) or indolent (slow-growing).

Learn more about the condition, treatments, and pipeline therapies @ Non-Hodgkin’s Lymphoma Pipeline Assessment 

Non-Hodgkin’s Lymphoma Pipeline Drugs 

Drug Company Phase MoA RoA
Venetoclax AbbVie III Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors Oral
Ibrutinib Janssen III Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors Oral
Naratuximab emtansine Debiopharm II Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerization inhibitors Intravenous
NKTR-255 Nektar Therapeutics II Antibody-dependent cell cytotoxicity; Interleukin-15 receptor agonists Intravenous
LOXO-305 Loxo Oncology II Agammaglobulinaemia tyrosine kinase inhibitors Oral
LAM–002 AI Therapeutics II Immunosuppressants; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PIKFYVE protein inhibitors Oral
CNCT19 Juventas Cell Therapy Ltd. II Immunologic cytotoxicity; T lymphocyte replacements Intravenous
GB226 Genor Biopharma II Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants Intravenous
BI-1206 BioInvent International I/II Antibody-dependent cell cytotoxicity; Fc gamma receptor IIB antagonists; T lymphocyte stimulants Intravenous
CAR-CD19 T Cells Carsgen therapeutics I/II Immunologic cytotoxicity; T lymphocyte replacements Intravenous
AUTO4 Autolus I/II Immunologic cytotoxicity; T lymphocyte replacements Intravenous
TT11 Tessa Therapeutics I Immunologic cytotoxicity; T lymphocyte replacements Pareneteral
CC-99282 Celgene I CRBN protein modulators; Ubiquitin protein ligase modulators Oral
AB-205 Angiocrine Bioscience I Cell replacements Intravenous

Request for Sample to know more @ Non-Hodgkin’s Lymphoma Pipeline Analysis, Key Companies, and Futuristic Trends 

Non-Hodgkin’s Lymphoma Therapeutics Assessment 

The Non-Hodgkin’s Lymphoma Pipeline report proffers an integral view of the Non-Hodgkin’s Lymphoma emerging novel therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

By Stage

  • Discovery 
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III

By Molecule Type 

  • Small molecules
  • Monoclonal antibodies

By Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Injectable

By Mechanism of Action

  • CD20 antigen inhibitors
  • CD-19 Antagonist
  • Emt protein-tyrosine kinase inhibitors
  • Cyclin-dependent kinase 6 inhibitors
  • Pyruvate dehydrogenase complex inhibitors
  • Proto-oncogene protein c-bcl-2 inhibitors
  • CRBN protein modulators; Ubiquitin protein ligase modulators
  • Cell replacements
  • Immunologic cytotoxicity; T lymphocyte replacements

By Targets

  • Protein
  • Lymphocytes
  • Lymphocyte Antigens

For rich insights into emerging therapies and assessment, visit Non-Hodgkin’s Lymphoma Pipeline Emerging Novel Therapies 

Scope of the Non-Hodgkin’s Lymphoma Drug Pipeline Report

Coverage: Global

Key Players: Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, among others.

Key Non-Hodgkin’s Lymphoma Pipeline Therapies: Obinutuzumab, Abemaciclib, Ibrutinib, CPI 818, Devimistat, Venetoclax, Loncastuximab tesirine, Venetoclax, Loncastuximab tesirine, LAM-002, HMPL-523, Venetoclax, Ibrutinib, Naratuximab emtansine, NKTR-255, LOXO-305, LAM–002, CNCT19, GB226, BI-1206, CAR-CD19 T Cells, AUTO4, TT11, CC-99282, AB-205,  and several others. 

Discover more about the scope of the report @ Non-Hodgkin’s Lymphoma Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

1 Report Introduction
2 Executive Summary
3 Non-Hodgkin’s Lymphoma Disease Overview
4 Non-Hodgkin’s Lymphoma Pipeline Therapeutics Comparative Analysis
5 Non-Hodgkin’s Lymphoma Therapeutics Assessment
6 In-depth Commercial Assessment
7 Non-Hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective
8 In-depth Commercial Non-Hodgkin’s Lymphoma Assessment
9 Non-Hodgkin’s Lymphoma Collaboration Deals 
10 Late Stage Non-Hodgkin’s Lymphoma Products (Phase III)
11 Mid-Stage Non-Hodgkin’s Lymphoma Products (Phase II)
12 Early Stage Non-Hodgkin’s Lymphoma Products (Phase I)
13 Pre-clinical and Discovery Stage Non-Hodgkin’s Lymphoma Products
14 Inactive Non-Hodgkin’s Lymphoma Pipeline Products 
  Key Non-Hodgkin’s Lymphoma Products
16 Unmet Needs
17 Non-Hodgkin’s Lymphoma Market Drivers and Barriers
18 Future Perspectives and Conclusion
19 Analyst Views
20 Key Non-Hodgkin’s Lymphoma Companies
21 Appendix

Learn more about the report offerings @ Non-Hodgkin’s Lymphoma Pipeline Therapies and Emerging Trends 

Audit the market domain before foraying, with DelveInsight’s Due Diligence Services  

Related Reports

Non-Hodgkin’s Lymphoma Market
DelveInsight’s “Non-Hodgkin’s Lymphoma (Non-Hodgkin’s Lymphoma) Market Insights, Epidemiology and Market Forecast-2028” report.

Car T Cell Therapy for Non-Hodgkin’s Lymphoma Market
DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) – Market Insights and Market Forecast-2030’ report.

B Cell Non-Hodgkin Lymphoma Market
DelveInsight’s “B-Cell Non-Hodgkin Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report.

Androgenetic Alopecia Market
DelveInsight’s “Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast-2030” report.

Browse through our posts 

Rare Cancer Market
Cancer Cachexia Pipeline Landscape
Cervical Cancer Market 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 



Source link

Related Posts

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More